NGL FINECHEM
|
NGL FINECHEM Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 66.63 | 33.04 | 80.68 | 91.58 | 13.14 |
| CEPS(Rs) | 85.72 | 51.45 | 97.55 | 105.30 | 26.62 |
| DPS(Rs) | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
| Book NAV/Share(Rs) | 425.11 | 360.23 | 328.94 | 250.01 | 160.18 |
| Tax Rate(%) | 24.07 | 25.09 | 25.08 | 26.90 | 30.96 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.87 | 12.57 | 21.48 | 31.05 | 13.03 |
| EBIT Margin(%) | 16.60 | 10.50 | 21.58 | 30.93 | 9.69 |
| Pre Tax Margin(%) | 16.07 | 9.84 | 20.98 | 30.08 | 7.96 |
| PAT Margin (%) | 12.20 | 7.37 | 15.72 | 21.99 | 5.50 |
| Cash Profit Margin (%) | 15.64 | 11.43 | 18.98 | 25.22 | 10.84 |
| Performance Ratios | |||||
| ROA(%) | 12.86 | 7.27 | 20.61 | 31.42 | 5.50 |
| ROE(%) | 17.03 | 9.63 | 27.90 | 44.76 | 8.72 |
| ROCE(%) | 20.38 | 11.96 | 33.91 | 53.53 | 11.93 |
| Asset Turnover(x) | 1.05 | 0.99 | 1.31 | 1.43 | 1.00 |
| Sales/Fixed Asset(x) | 2.36 | 2.07 | 2.82 | 2.75 | 1.83 |
| Working Capital/Sales(x) | 2.69 | 2.66 | 2.94 | 3.12 | 4.01 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.42 | 0.48 | 0.36 | 0.36 | 0.55 |
| Receivable days | 83.78 | 85.22 | 58.36 | 45.10 | 71.37 |
| Inventory Days | 37.88 | 54.47 | 53.95 | 46.51 | 55.95 |
| Payable days | 85.07 | 75.67 | 72.38 | 78.66 | 98.81 |
| Valuation Parameters | |||||
| PER(x) | 31.37 | 36.22 | 24.27 | 16.74 | 19.28 |
| PCE(x) | 24.38 | 23.26 | 20.07 | 14.56 | 9.52 |
| Price/Book(x) | 4.92 | 3.32 | 5.95 | 6.13 | 1.58 |
| Yield(%) | 0.08 | 0.15 | 0.09 | 0.11 | 0.69 |
| EV/Net Sales(x) | 3.91 | 2.73 | 3.90 | 3.72 | 1.20 |
| EV/Core EBITDA(x) | 19.50 | 18.74 | 15.70 | 10.88 | 7.96 |
| EV/EBIT(x) | 23.54 | 25.99 | 18.08 | 12.02 | 12.35 |
| EV/CE(x) | 4.46 | 2.98 | 4.47 | 4.62 | 1.18 |
| M Cap / Sales | 3.81 | 2.66 | 3.81 | 3.67 | 1.03 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 21.79 | -12.42 | 23.08 | 70.07 | -0.97 |
| Core EBITDA Growth(%) | 67.63 | -48.67 | -10.49 | 286.35 | -37.36 |
| EBIT Growth(%) | 92.58 | -57.38 | -14.14 | 442.89 | -51.19 |
| PAT Growth(%) | 101.58 | -58.92 | -12.03 | 580.47 | -58.59 |
| EPS Growth(%) | 101.66 | -59.05 | -11.91 | 597.04 | -59.67 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.13 | 0.15 | 0.15 | 0.11 | 0.29 |
| Current Ratio(x) | 2.46 | 2.79 | 2.64 | 2.98 | 1.88 |
| Quick Ratio(x) | 1.96 | 2.33 | 1.79 | 2.08 | 1.23 |
| Interest Cover(x) | 31.07 | 15.92 | 35.81 | 36.21 | 5.60 |
| Total Debt/Mcap(x) | 0.03 | 0.04 | 0.02 | 0.02 | 0.18 |
Compare Financial Ratios of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,021.9 Cr | -2.7% | -10.3% | -17.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹421,527.0 Cr | -3.7% | -2.5% | 31.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,037.0 Cr | 2.3% | 2.1% | 46.9% | Stock Analytics | |
| CIPLA | ₹116,854.0 Cr | -3.2% | 0% | 8.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,746.0 Cr | -2.4% | 7.3% | 15.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹99,093.9 Cr | 2% | 2.3% | 37.9% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -2.7% |
-10.3% |
-17.9% |
| SENSEX | -1.8% |
-6.6% |
7.1% |
You may also like the below Video Courses
